CAVA’s (NYSE:CAVA) Q2 CY2026 Sales Beat Estimates, Stock Jumps 10.2%

CAVA (NYSE:CAVA) reported Q2 CY2026 results. Revenue rose 31.3% year on year to $368.4 million, beating Wall Street estimates by 2.4%, and GAAP EPS was $0.19, in line with consensus. The company had 476 locations and same-store sales up 9% y/y. Shares jumped 10.2% to $67.62 after the report.

Original reporting
Published Aug 11, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 10:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CAVA’s (NYSE:CAVA) Q2 CY2026 Sales Beat Estimates, Stock Jumps 10.2% — source image
Decision brief

The 30-second read

$CAVABullishMed
01

Why it matters

Q2 results show strong demand and organic performance, but the full-year EBITDA guidance miss introduces uncertainty about profitability and could influence valuation multiples.

02

Market read

This is a company-specific earnings catalyst with a clear beat on revenue and same-store sales, partially offset by weaker full-year EBITDA guidance.

03

What to watch

The article does not quantify the magnitude of the EBITDA miss or provide margin drivers, so traders may be over-weighting the sales beat versus profitability trajectory.

Relevance 8/10Novelty 6/10Timing: after-hours/next-session reaction following Q2 CY2026 results

Background

CAVA is a fast-casual Mediterranean restaurant chain expanding both through new locations and same-store sales growth.

Company-level read

Ticker impact

$CAVABullishMedium confidence
Context

CAVA reported Q2 CY2026 revenue up 31.3% to $368.4 million, beating Wall Street estimates by 2.4%, and shares jumped 10.2% to $67.62.

Expected impact

Near-term bias remains positive, with follow-through dependent on whether EBITDA guidance is revised or margins improve.

Evidence & confidence

The article provides a concrete earnings datapoint (revenue beat, same-store sales up 9% YoY) plus a key offset (full-year EBITDA guidance missed), which typically drives initial upside but can cap sustained rallies.

Market effects

Reinforces demand strength for Mediterranean fast-casual concepts, but the EBITDA guidance miss highlights margin sensitivity in the sector.

No specific regional impact beyond CAVA’s continued restaurant expansion.

Limited, as this is company-specific earnings performance.

Counterpoint

The revenue beat may reflect top-line momentum while the full-year EBITDA guidance miss signals cost or margin pressure that could reassert itself.

Key entities

  • CAVA

    Reported Q2 CY2026 revenue and same-store sales results, with a full-year EBITDA guidance miss and a 10.2% stock jump.

Related articles

$CAVAMedAI 8/10

Cava beats quarterly expectations on Mediterranean cuisine demand

Reuters reports Cava Group beat Q2 expectations, with same-restaurant sales up 9% and guest traffic up 5.3%. Revenue rose 31.3% to $365.4 million and adjusted EBITDA rose 30% to $54.7 million. July food-safety concerns hurt sales, but Cava said it was not linked to related outbreaks and forecasts for FY2026 were reiterated.

$CRWVHighAI 8/10

After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB

After-hours trading saw gains in CoreWeave (CRWV) after a smaller-than-expected Q2 loss of $1.14 per share on $2.58B revenue and a $104B backlog plus $25B+ Q3 commitments. Super Micro (SMCI) rose on Q4 results and Q1 FY2027 revenue guidance $14.5B-$15.5B. CAVA, LITE, and HRB also moved on quarterly beats and outlooks.

$CAVAHighAI 9/10

CAVA GROUP, INC. (CAVA): Results of Operations and Financial Condition

CAVA GROUP, INC. (CAVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 earningsrelease2026q2.htm EX-99.1 Document Exhibit 99.1 CAVA GROUP REPORTS SECOND QUARTER 2026 RESULTS ___________________________________________ YEAR OVER YEAR CAVA REVENUE GROWTH OF 31.3% INCLUDING SAME RESTAURANT SALES OF 9.0% DRIVEN BY GUEST TRAFFIC GROWTH OF 5.3%

$CAVAMed

Cava Founders and Board Accused of Insider Trading in $2.2 Billion Case: Report

A lawsuit reported by Bloomberg Law accuses Cava Group Inc. founders and board chair Ronald Shaich, plus financial backers, of insider trading. It alleges nearly $2.2 billion in stock sales from Aug 2024 to Mar 2025 while allegedly hiding slowing growth. Cava says the suit is without merit and will defend. Cava trades around $65.85 as of July 31.